News

Zelluna ASA Executes Successful 10-for-1 Share Consolidation

Zelluna ASA Executes Successful 10-for-1 Share Consolidation

Zelluna ASA Completes Significant Share Structure Adjustment

Zelluna ASA, a pioneering company in the biotech industry, has successfully registered a reverse share split with a 10 to 1 ratio. This achievement marks a critical milestone for the company, which focuses on advancing innovative treatments for cancer.

Details of the Share Split

The reverse share split is now officially recorded with the Norwegian Register of Business Enterprises. As a result, the total number of outstanding shares in Zelluna ASA is now 20,227,066, with each share having a par value of NOK 1. This strategic move is designed to streamline the company’s share structure, potentially enhancing the accessibility and attractiveness of their stock to investors.

Leadership Insights on the Transformation

Hans Vassgård Eid, the Chief Financial Officer of Zelluna ASA, emphasized the importance of this move for the company's future. “This consolidation empowers us to pursue complex strategies in the market, aligning with our long-term vision. We believe this shift will offer more opportunities for growth and investment,” he stated.

Company Mission and Innovations

Zelluna's core mission revolves around delivering groundbreaking therapies capable of curing advanced solid cancers efficiently and safely. Leveraging the immune system’s most powerful components, Zelluna is focused on developing "off the shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies. With this innovative approach, they aim to address the complexity and diversity of cancer.

Upcoming Projects

One of Zelluna's notable projects is the world’s first MAGE-A4 targeting “off the shelf” TCR-NK therapy, which promises to be a game-changer in the treatment of solid cancers. In addition to this flagship initiative, a robust pipeline of therapies is in development to broaden their impact in the oncology space.

Strategic Vision for Future Growth

Looking ahead, Zelluna ASA is positioned to make significant strides in cancer therapy. The management team, comprised of seasoned biotech entrepreneurs, is dedicated to advancing from discovery to clinical development, ensuring that innovative cell-based therapies are brought to market. This strategic direction reflects their commitment to overcoming the challenges in current cancer treatments.

Contact Information

For additional queries or more information about Zelluna ASA, you can reach out to:

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com
Phone: +47 482 48632

Frequently Asked Questions

What is the purpose of the reverse share split at Zelluna ASA?

The reverse share split aims to enhance the company’s share structure, making it more attractive to potential investors.

How will the reverse share split affect the current shareholders?

Shareholders will see their total number of shares decrease by a factor of 10 while maintaining equivalent ownership value.

What innovations is Zelluna ASA working on?

Zelluna is focused on developing advanced TCR-NK cell therapies targeting solid cancers, with multiple therapies in the pipeline.

Who can shareholders contact for more information?

Shareholders can contact Hans Vassgård Eid, the CFO, for any queries or additional information.

What does "off the shelf" therapy mean?

“Off the shelf” therapies refer to ready-made treatments that can be used immediately, without the need for customization for each individual patient.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 58

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 459

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 318

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 19

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading

Top 5 Most Recently Viewed Articles

Leidos' Autonomous Vessels Chart Bold Naval Waters

Updated Category News Views 49

Leidos' Autonomous Leap with the U.S. Navy Well, today it's all about Leidos, an outfit that's been showing its grit in the world of maritime autonomy. Their systems aren't just tinkering around anymore—they're slicing through the waves at RIMPAC, the Rim of the Pacific, and running alongside the USS Theodore Roosevelt Carrier Strike Group. That's big news in anyone's...

Continue Reading
89bio to Showcase Pegozafermin Trial Insights at Major Conference

Updated Category News Views 67

89bio Presents Key Findings from ENLIVEN Phase 2b Trial 89bio, Inc. (NASDAQ: ETNB), a biopharmaceutical company committed to developing innovative treatments for liver and cardiometabolic diseases, has exciting news. The company will present new analyses from its Phase 2b ENLIVEN trial, which assesses the efficacy of pegozafermin in patients suffering from metabolic...

Continue Reading
New Insights on Penetrium's Role in Combating TNBC Growth

Updated Category News Views 487

Hyundai ADM Bio Unveils Promising Results for Penetrium – Groundbreaking treatment strategy targets both primary and metastatic tumors. Hyundai ADM Bio has announced significant findings related to its pioneering agent, Penetrium, which exhibited impressive anti-metastatic properties in recent preclinical studies involving triple-negative breast cancer (TNBC). This...

Continue Reading
Designer Brands Inc. Reveals Upcoming Earnings Call for Q1 2025

Updated Category News Views 178

Upcoming Earnings Release for Designer Brands Inc. Designer Brands Inc. (NYSE: DBI), a leading force in footwear and accessories, has announced an important date for shareholders and interested parties alike. The company is set to release its earnings for the first quarter of 2025 on June 10, 2025. This marks a significant event, as it gives insights into the company's...

Continue Reading
Harvard Bioscience, Inc. Reports Q1 2025 Financial Performance

Updated Category News Views 374

Strong Financial Insights from Harvard Bioscience Harvard Bioscience, Inc. (NASDAQ: HBIO) recently shared its financial results for the first quarter, showcasing a mixed performance influenced by various market factors. The company expressed confidence in its revenue management and highlighted new product developments that are energizing its business strategies. Revenue...

Continue Reading